Novartis: Recent Selloff Has Presented A Buying Opportunity [Seeking Alpha]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Seeking Alpha
SummaryNovartis has multiple growth assets in its portfolio.The company is rapidly launching new drugs.Investors should be aware of risks posed by competitive pressures, generic erosion, and FDA recalls.Novartis (NVSNovartis is a big pharma company increasingly focused on high growth areas such as rare diseases, gene therapy, and oncology. The company is also targeting the large underserved markets of psoriasis and multiple sclerosis. With new management at the helm, the company is aggressively trying to become more focused and nimbler like a biotech company. Novartis completed five commercial launches in 2019, which is a feat even for a biotech company and much more so for a big pharma company. Finally, the company pays healthy dividends to its shareholders. Novartis can thus offer an appealing mix of value, growth, and income to retail investors.Novartis has been reporting promising financial performanceIn 2019, Novartis reported net sales of $47.4 billion, a YoY rise of 9% on CC (c
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Velocity targets Latin America expansion with the appointment of Renata Berardocco as LATAM Managing Director [Yahoo! Finance]Yahoo! Finance
- Swiss pharma giant Novartis says 30 pipeline drugs with ‘significant potential' will drive long-term growth [Fortune]Fortune
- BerGenBio Appoints Olav Hellebø as CEO [Yahoo! Finance]Yahoo! Finance
- Vyriad announces strategic collaboration with Novartis to develop in vivo CAR-T cell therapies [Yahoo! Finance]Yahoo! Finance
- NUCLIDIUM Appoints Tony Rosenberg as Chairman of the Board [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 10/29/24 - Beat
NVS
Sec Filings
- 10/29/24 - Form 6-K
- 10/29/24 - Form 6-K
- 9/18/24 - Form 6-K
- NVS's page on the SEC website